Targeting the endoplasmic reticulum in prion disease treatment: breakthroughs and challenges

References

• Prusiner SB. Prions. Proc Natl Acad Sci U S A. 1998;95(23):13363–13383.
   PubMed Web of Science ®Google Scholar
• Baldwin MA. Analysis of glycosylphosphatidylinositol protein anchors: the prion protein. Methods Enzymol. 2005;405:172–187.
   Web of Science ®Google Scholar
• Hegde RS, Mastrianni JA, Scott MR, et al. A transmembrane form of the prion protein in neurodegenerative disease. Science. 1998;279(5352):827–834.
   Web of Science ®Google Scholar
• Griffith JS. Self-replication and scrapie. Nature. 1967;215(5105):1043–1044.
   PubMed Web of Science ®Google Scholar
• Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science. 1982;216(4542):136–144.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Xiao G. Conformational conversion of prion protein in prion diseases. Acta Biochim Biophys Sin. 2013;45(6):465–476.
   Google Scholar
• Yuan Z, Zhao D, Yang L. Decipher the mechanisms of rabbit’s low susceptibility to prion infection. Acta Biochim Biophys Sin. 2013;45(11):899–903.
   Google Scholar
• Colby DW, Prusiner SB. Prions. Cold Spring Harb Perspect Biol. 2011;3:a006833.
   PubMed Web of Science ®Google Scholar
• Moreno-Gonzalez I, Soto C. Misfolded protein aggregates: mechanisms, structures and potential for disease transmission. Semin Cell Dev Biol. 2011;22(5):482–487.
   PubMed Web of Science ®Google Scholar
• Surewicz WK, Apostol MI. Prion protein and its conformational conversion: a structural perspective. Top Curr Chem. 2011;305:135–167.
   Web of Science ®Google Scholar
• Legname G, Baskakov IV, Nguyen HO, et al. Synthetic mammalian prions. Science. 2004;305(5684):673–676.
   PubMed Web of Science ®Google Scholar
• Castilla J, Saá P, Hetz C, Soto C. In vitro generation of infectious scrapie prions. Cell. 2005;121(2):195–206.
   PubMed Web of Science ®Google Scholar
• Deleault NR, Harris BT, Rees JR, Supattapone S. Formation of native prions from minimal components in vitro. Proc Natl Acad Sci U S A. 2007;104(23):9741–9746.
   Web of Science ®Google Scholar
• Wang F, Wang X, Yuan CG, Ma J. Generating a prion with bacterially expressed recombinant prion protein. Science. 2010;327(5969):1132–1135.
   PubMed Web of Science ®Google Scholar
• Come JH, Fraser PE, Lansbury PT Jr. A kinetic model for amyloid formation in the prion diseases: importance of seeding. Proc Natl Acad Sci U S A. 1993;90(13):5959–5963.
   Web of Science ®Google Scholar
• Büeler H, Aguzzi A, Sailer A, et al. Mice devoid of PrP are resistant to scrapie. Cell. 1993;73(7):1339–1347.
   PubMed Web of Science ®Google Scholar
• Manson JC, Clarke AR, Hooper ML, Aitchison L, McConnell I, Hope J. 129/Ola mice carrying a null mutation in PrP that abolishes mRNA production are developmentally normal. Mol Neurobiol. 1994;8(2–3):121–127.
   PubMed Web of Science ®Google Scholar
• Brown DR, Qin K, Herms JW, et al. The cellular prion protein binds copper in vivo. Nature. 1997;390(6661):684–687.
   PubMed Web of Science ®Google Scholar
• Jackson GS, Murray I, Hosszu LL, et al. Location and properties of metal-binding sites on the human prion protein. Proc Natl Acad Sci U S A. 2001;98(15):8531–8535.
   Web of Science ®Google Scholar
• Brown DR, Sassoon J. Copper-dependent functions for the prion protein. Mol Biotechnol. 2002;22(2):165–1678.
   PubMed Web of Science ®Google Scholar
• Khosravani H, Zhang Y, Tsutsui S, et al. Prion protein attenuates excitotoxicity by inhibiting NMDA receptors. J Cell Biol. 2008;181(3):551–565.
   PubMed Web of Science ®Google Scholar
• You H, Tsutsui S, Hameed S, et al. Aβ neurotoxicity depends on interactions between copper ions, prion protein, and N-methyl-D-aspartate receptors. Proc Natl Acad Sci U S A. 2012;109(5):1737–1742.
   PubMed Web of Science ®Google Scholar
• Mastrianni JA. The genetics of prion diseases. Genet Med. 2010;12(4):187–195.
   PubMed Web of Science ®Google Scholar
• Puoti G, Bizzi A, Forloni G, Safar JG, Tagliavini F, Gambetti P. Sporadic human prion diseases: molecular insights and diagnosis. Lancet Neurol. 2012;11(7):618–628.
   PubMed Web of Science ®Google Scholar
• Goldfarb LG, Petersen RB, Tabaton M, et al. Fatal familial insomnia and familial Creutzfeldt-Jakob disease: disease phenotype determined by a DNA polymorphism. Science. 1992;258(5083):806–808.
   PubMed Web of Science ®Google Scholar
• Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol. 2007;8(7):519–529.
   PubMed Web of Science ®Google Scholar
• Harding HP, Zhang Y, Ron D. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature. 1999;397(6716):271–274.
   PubMed Web of Science ®Google Scholar
• Novoa I, Zeng H, Harding H, Ron D. Feedback inhibition of the unfolded protein response by GADD34-mediated dephosphorylation of eIF2α. J Cell Biol. 2001;153(5):1011–1022.
   PubMed Web of Science ®Google Scholar
• Yoshida H, Matsui T, Yamamoto A, Okada T, Mori K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell. 2001;107(7):881–891.
   PubMed Web of Science ®Google Scholar
• Lee AH, Iwakoshi NN, Glimcher LH. XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response. Mol Cell Biol. 2003;23(21):7448–7459.
   PubMed Web of Science ®Google Scholar
• Yoshida H, Haze K, Yanagi H, Yura T, Mori K. Identification of the cis-acting endoplasmic reticulum stress response element responsible for transcriptional induction of mammalian glucose-regulated proteins. Involvement of basic leucine zipper transcription factors. J Biol Chem. 1998;273(50):33741–33749.
   PubMed Web of Science ®Google Scholar
• Haze K, Yoshida H, Yanagi H, Yura T, Mori K. Mammalian transcription factor ATF6 is synthesized as a transmembrane protein and activated by proteolysis in response to endoplasmic reticulum stress. Mol Biol Cell. 1999;10(11):3787–3799.
   PubMed Web of Science ®Google Scholar
• Li M, Baumeister P, Roy B, et al. ATF6 as a transcription activator of the endoplasmic reticulum stress element: thapsigargin stress-induced changes and synergistic interactions with NF-Y and YY1. Mol Cell Biol. 2000;20(14):5096–5106.
   PubMed Web of Science ®Google Scholar
• Hetz C, Russelakis-Carneiro M, Maundrell K, Castilla J, Soto C. Caspase-12 and endoplasmic reticulum stress mediate neurotoxicity of pathological prion protein. EMBO J. 2003;22(20):5435–5445.
   Web of Science ®Google Scholar
• Yoo BC, Krapfenbauer K, Cairns N, Belay G, Bajo M, Lubec G. Overexpressed protein disulfide isomerase in brains of patients with sporadic Creutzfeldt–Jakob disease. Neurosci Lett. 2002;334(3):196–200.
   Web of Science ®Google Scholar
• Hetz C, Castilla J, Soto C. Perturbation of endoplasmic reticulum homeostasis facilitates prion replication. J Biol Chem. 2007;282(17):12725–12733.
   Web of Science ®Google Scholar
• Torres M, Castillo K, Armisén R, Stutzin A, Soto C, Hetz C. Prion protein misfolding affects calcium homeostasis and sensitizes cells to endoplasmic reticulum stress. PLoS One. 2010;5(12):e15658.
   Web of Science ®Google Scholar
• Shi Q, Dong XP. (Ctm)PrP and ER stress: a neurotoxic mechanism of some special PrP mutants. Prion. 2011;5(3):123–125.
   PubMed Web of Science ®Google Scholar
• Castilla J, Hetz C, Soto C. Molecular mechanisms of neurotoxicity of pathological prion protein. Curr Mol Med. 2004;4(4):397–403.
   Web of Science ®Google Scholar
• Ferreiro E, Resende R, Costa R, Oliveira CR, Pereira CM. An endoplasmic-reticulum-specific apoptotic pathway is involved in prion and amyloid-beta peptides neurotoxicity. Neurobiol Dis. 2006;23(3):669–678.
   PubMed Web of Science ®Google Scholar
• Wang X, Shi Q, Xu K, et al. Familial CJD associated PrP mutants within transmembrane region induced Ctm-PrP retention in ER and triggered apoptosis by ER stress in SH-SY5Y cells. PLoS One. 2011;6(1):e14602.
   Web of Science ®Google Scholar
• Rane NS, Kang SW, Chakrabarti O, Feigenbaum L, Hegde RS. Reduced translocation of nascent prion protein during ER stress contributes to neurodegeneration. Dev Cell. 2008;15(3):359–370.
   Web of Science ®Google Scholar
• Nunziante M, Ackermann K, Dietrich K, et al. Proteasomal dysfunction and endoplasmic reticulum stress enhance trafficking of prion protein aggregates through the secretory pathway and increase accumulation of pathologic prion protein. J Biol Chem. 2011;286(39):33942–33953.
   Web of Science ®Google Scholar
• Ma J, Wollmann R, Lindquist S. Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol. Science. 2002;298(5599):1781–1785.
   PubMed Web of Science ®Google Scholar
• Peters JM, Franke WW, Kleinschmidt JA. Distinct 19 S and 20 S subcomplexes of the 26 S proteasome and their distribution in the nucleus and the cytoplasm. J Biol Chem. 1994;269(10):7709–7718.
   PubMed Web of Science ®Google Scholar
• Lodish HBA, Matsudaira P, Kaiser CA, et al. Molecular Cell Biology. 5th ed. New York: WH Freeman and Co; 2004:66–72.
   Google Scholar
• Baumeister W, Walz J, Zuhl F, Seemüller E. The proteasome: paradigm of a self-compartmentalizing protease. Cell. 1998;92(3):367–380.
   PubMed Web of Science ®Google Scholar
• Früh K, Gossen M, Wang K, Bujard H, Peterson PA, Yang Y. Displacement of housekeeping proteasome subunits by MHC-encoded LMPs: a newly discovered mechanism for modulating the multicatalytic proteinase complex. EMBO J. 1994;13:3236–3244.
   PubMed Web of Science ®Google Scholar
• Deriziotis P, André R, Smith DM, et al. Misfolded PrP impairs the UPS by interaction with the 20S proteasome and inhibition of substrate entry. EMBO J. 2011;30(15):3065–3077.
   Web of Science ®Google Scholar
• Deriziotis P, Tabrizi SJ. Prions and the proteasome. Biochim Biophys Acta. 2008;1782(12):713–722.
   Web of Science ®Google Scholar
• Kim BY, Olzmann JA, Barsh GS, Chin LS, Li L. Spongiform neurodegeneration-associated E3 ligase Mahogunin ubiquitylates TSG101 and regulates endosomal trafficking. Mol Biol Cell. 2007;18(4):1129–1142.
   Web of Science ®Google Scholar
• Lehman NL. The ubiquitin proteasome system in neuropathology. Acta Neuropathol. 2009;118:329–347.
   PubMed Web of Science ®Google Scholar
• Lloyd SE, Maytham EG, Pota H, et al. HECTD2 is associated with susceptibility to mouse and human prion disease. PLoS Genet. 2009;5(2):e1000383.
   PubMed Web of Science ®Google Scholar
• Mishra RS, Bose S, Gu Y, Li R, Singh N. Aggresome formation by mutant prion proteins: the unfolding role of proteasomes in familial prion disorders. J Alzheimers Dis. 2003;5(1):15–23.
   Web of Science ®Google Scholar
• Kristiansen M, Messenger MJ, Klöhn PC, et al. Disease-related prion protein forms aggresomes in neuronal cells leading to caspase activation and apoptosis. J Biol Chem. 2005;280(46):38851–38861.
   Web of Science ®Google Scholar
• Yorimitsu T, Nair U, Yang Z, Klionsky DJ. Endoplasmic reticulum stress triggers autophagy. J Biol Chem. 2006;281(40):30299–30304.
   PubMed Web of Science ®Google Scholar
• Ogata M, Hino S, Saito A, et al. Autophagy is activated for cell survival after endoplasmic reticulum stress. Mol Cell Biol. 2006;26(24):9220–9231.
   PubMed Web of Science ®Google Scholar
• Bernales S, McDonald KL, Walter P. Autophagy counterbalances endoplasmic reticulum expansion during the unfolded protein response. PLoS Biol. 2006;4(12):e423.
   PubMed Web of Science ®Google Scholar
• Rubinsztein DC, DiFiglia M, Heintz N, et al. Autophagy and its possible roles in nervous system diseases, damage and repair. Autophagy. 2005;1(1):11–22.
   PubMed Web of Science ®Google Scholar
• Heiseke A, Aguib Y, Schatzl HM. Autophagy, prion infection and their mutual interactions. Curr Issues Mol Biol. 2010;12(2):87–97.
   PubMedGoogle Scholar
• Boellaard JW, Schlote W, Tateishi J. Neuronal autophagy in experimental Creutzfeldt–Jakob’s disease. Acta Neuropathol. 1989;78(4):410–418.
   Web of Science ®Google Scholar
• Boellaard JW, Kao M, Schlote W, Diringer H. Neuronal autophagy in experimental scrapie. Acta Neuropathol. 1991;82(3):225–228.
   Web of Science ®Google Scholar
• Schätzl HM, Laszlo L, Holtzman DM, et al. A hypothalamic neuronal cell line persistently infected with scrapie prions exhibits apoptosis. J Virol. 1997;71(11):8821–8831.
   Web of Science ®Google Scholar
• Xu Y, Tian C, Wang SB, et al. Activation of the macroautophagic system in scrapie-infected experimental animals and human genetic prion diseases. Autophagy. 2012;8(11):1604–1620.
   PubMed Web of Science ®Google Scholar
• Cortes CJ, Qin K, Norstrom EM, Green WN, Bindokas VP, Mastrianni JA. Early delivery of misfolded PrP from ER to lysosomes by autophagy. Int J Cell Biol. 2013;2013:560421.
   Google Scholar
• Cortes CJ, Qin K, Cook J, Solanki A, Mastrianni JA. Rapamycin delays disease onset and prevents PrP plaque deposition in a mouse model of Gerstmann-Sträussler-Scheinker disease. J Neurosci. 2012;32(36):12396–12405.
   PubMed Web of Science ®Google Scholar
• Yun SW, Ertmer A, Flechsig E, et al. The tyrosine kinase inhibitor imatinib mesylate delays prion neuroinvasion by inhibiting prion propagation in the periphery. J Neurovirol. 2007;13(4):328–337.
   PubMed Web of Science ®Google Scholar
• Heiseke A, Aguib Y, Riemer C, Baier M, Schätzl HM. Lithium induces clearance of protease resistant prion protein in prion-infected cells by induction of autophagy. J Neurochem. 2009;109(1):25–34.
   PubMed Web of Science ®Google Scholar
• Aguib Y, Heiseke A, Gilch S, et al. Autophagy induction by trehalose counteracts cellular prion infection. Autophagy. 2009;5(3):361–369.
   PubMed Web of Science ®Google Scholar
• Yao H, Zhao D, Khan SH, Yang L. Role of autophagy in prion protein-induced neurodegenerative diseases. Acta Biochim Biophys Sin (Shanghai). 2013;45(6):494–502.
   Web of Science ®Google Scholar
• Wong E, Cuervo AM. Autophagy gone awry in neurodegenerative diseases. Nat Neurosci. 2010;13(7):805–811.
   PubMed Web of Science ®Google Scholar
• Belichenko PV, Brown D, Jeffrey M, Fraser JR. Dendritic and synaptic alterations of hippocampal pyramidal neurones in scrapie-infected mice. Neuropathol Appl Neurobiol. 2000;26(2):143–149.
   Web of Science ®Google Scholar
• Jeffrey M, Halliday WG, Bell J, et al. Synapse loss associated with abnormal PrP precedes neuronal degeneration in the scrapie-infected murine hippocampus. Neuropathol Appl Neurobiol. 2000;26(1):41–54.
   PubMed Web of Science ®Google Scholar
• Brown D, Belichenko P, Sales J, Jeffrey M, Fraser JR. Early loss of dendritic spines in murine scrapie revealed by confocal analysis. Neuroreport. 2001;12(1):179–183.
   Web of Science ®Google Scholar
• Cunningham C, Deacon R, Wells H, et al. Synaptic changes characterize early behavioural signs in the ME7 model of murine prion disease. Eur J Neurosci. 2003;17(10):2147–2155.
   Web of Science ®Google Scholar
• Chiti Z, Knutsen OM, Betmouni S, Greene JR. An integrated, temporal study of the behavioural, electrophysiological and neuropathological consequences of murine prion disease. Neurobiol Dis. 2006;22(2):363–373.
   Web of Science ®Google Scholar
• Mallucci GR, White MD, Farmer M, et al. Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. Neuron. 2007;53(3):325–335.
   PubMed Web of Science ®Google Scholar
• Gray BC, Siskova Z, Perry VH, O’Connor V. Selective presynaptic degeneration in the synaptopathy associated with ME7-induced hippocampal pathology. Neurobiol Dis. 2009;35(1):63–74.
   Web of Science ®Google Scholar
• Sisková Z, Page A, O’Connor V, Perry VH. Degenerating synaptic boutons in prion disease: microglia activation without synaptic stripping. Am J Pathol. 2009;175(4):1610–1621.
   Web of Science ®Google Scholar
• Moreno JA, Radford H, Peretti D, et al. Sustained translational repression by eIF2α-P mediates prion neurodegeneration. Nature. 2012;485(7399):507–511.
   PubMed Web of Science ®Google Scholar
• Moreno JA, Halliday M, Molloy C, et al. Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice. Sci Transl Med. 2013;5(206):206ra138.
   PubMed Web of Science ®Google Scholar
• Mukherjee A, Morales-Scheihing D, Gonzalez-Romero D, Green K, Taglialatela G, Soto C. Calcineurin inhibition at the clinical phase of prion disease reduces neurodegeneration, improves behavioral alterations and increases animal survival. PLoS Pathog. 2010;6(10):e1001138.
   Web of Science ®Google Scholar
• Stewart RS, Piccardo P, Ghetti B, Harris DA. Neurodegenerative illness in transgenic mice expressing a transmembrane form of the prion protein. J Neurosci. 2005;25(13):3469–3477.
   PubMed Web of Science ®Google Scholar
• Quaglio E, Restelli E, Garofoli A, et al. Expression of mutant or cytosolic PrP in transgenic mice and cells is not associated with endoplasmic reticulum stress or proteasome dysfunction. PLoS One. 2011;6(4):e19339.
   Web of Science ®Google Scholar
• Biasini E, Massignan T, Fioriti L, et al. Analysis of the cerebellar proteome in a transgenic mouse model of inherited prion disease reveals preclinical alteration of calcineurin activity. Proteomics. 2006;6(9):2823–2834.
   Web of Science ®Google Scholar
• Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NB, Hamid M. scFv antibody: principles and clinical application. Clin Dev Immunol. 2012;2012:980250.
   PubMed Web of Science ®Google Scholar
• Malone J, Sullivan MA. Analysis of antibody selection by phage display utilizing anti-phenobarbital antibodies. J Mol Recognit. 1996;9(5–6):738–745.
   Web of Science ®Google Scholar
• Huang L, Su X, Federoff HJ. Single-chain fragment variable passive immunotherapies for neurodegenerative diseases. Int J Mol Sci. 2013;14(9):19109–19127.
   PubMed Web of Science ®Google Scholar
• Filesi I, Cardinale A, Mattei S, Biocca S. Selective re-routing of prion protein to proteasomes and alteration of its vesicular secretion prevent PrP(Sc) formation. J Neurochem. 2007;101(6):1516–1526.
   PubMed Web of Science ®Google Scholar
• Cardinale A, Filesi I, Vetrugno V, Pocchiari M, Sy MS, Biocca S. Trapping prion protein in the endoplasmic reticulum impairs PrPC maturation and prevents PrPSc accumulation. J Biol Chem. 2005;280(1):685–694.
   PubMed Web of Science ®Google Scholar
• Biocca S, Ruberti F, Tafani M, Pierandrei-Amaldi P, Cattaneo A. Redox state of single chain Fv fragments targeted to the endoplasmic reticulum, cytosol and mitochondria. Biotechnology (N Y). 1995;13(10):1110–1115.
   Google Scholar
• Cardinale A, Biocca S. Gene-based antibody strategies for prion diseases. Int J Cell Biol. 2013;2013:710406.
   PubMedGoogle Scholar
• Wuertzer CA, Sullivan MA, Qiu X, Federoff HJ. CNS delivery of vectored prion-specific single-chain antibodies delays disease onset. Mol Ther. 2008;16(3):481–486.
   PubMed Web of Science ®Google Scholar
• Donofrio G, Heppner FL, Polymenidou M, Musahl C, Aguzzi A. Paracrine inhibition of prion propagation by anti-PrP single-chain Fv miniantibodies. J Virol. 2005;79(13):8330–8338.
   PubMed Web of Science ®Google Scholar
• Fujita K, Yamaguchi Y, Mori T, et al. Effects of a brain-engraftable microglial cell line expressing anti-prion scFv antibodies on survival times of mice infected with scrapie prions. Cell Mol Neurobiol. 2011;31(7):999–1008.
   PubMed Web of Science ®Google Scholar
• Gauczynski S, Hundt C, Leucht C, Weiss S. Interaction of prion proteins with cell surface receptors, molecular chaperones, and other molecules. Adv Protein Chem. 2001;57:229–272.
   PubMedGoogle Scholar
• Gauczynski S, Nikles D, El-Gogo S, et al. The 37-kDa/67-kDa laminin receptor acts as a receptor for infectious prions and is inhibited by polysulfated glycanes. J Infect Dis. 2006;194(5):702–709.
   PubMed Web of Science ®Google Scholar
• Vana K, Weiss S. A trans-dominant negative 37kDa/67kDa laminin receptor mutant impairs PrP(Sc) propagation in scrapie-infected neuronal cells. J Mol Biol. 2006;358(1):57–66.
   Web of Science ®Google Scholar
• Ludewigs H, Zuber C, Vana K, Nikles D, Zerr I, Weiss S. Therapeutic approaches for prion disorders. Expert Rev Anti Infect Ther. 2007;5(4):613–630.
   PubMed Web of Science ®Google Scholar
• Morel E, Andrieu T, Casagrande F, et al. Bovine prion is endocytosed by human enterocytes via the 37 kDa/67 kDa laminin receptor. Am J Pathol. 2005;167(4):1033–1042.
   Web of Science ®Google Scholar
• Zuber C, Knackmuss S, Rey C, et al. Single chain Fv antibodies directed against the 37 kDa/67 kDa laminin receptor as therapeutic tools in prion diseases. Mol Immunol. 2008;45(1):144–151.
   PubMed Web of Science ®Google Scholar
• Zuber C, Mitteregger G, Schuhmann N, et al. Delivery of single-chain antibodies (scFvs) directed against the 37/67 kDa laminin receptor into mice via recombinant adeno-associated viral vectors for prion disease gene therapy. J Gen Virol. 2008;89(Pt 8):2055–2061.
   PubMedGoogle Scholar
• Jiang P, Gan M, Ebrahim AS, Lin WL, Melrose HL, Yen SH. ER stress response plays an important role in aggregation of α-synuclein. Mol Neurodegener. 2010;5:56.
   PubMed Web of Science ®Google Scholar
• Colla E, Jensen PH, Pletnikova O, Troncoso JC, Glabe C, Lee MK. Accumulation of toxic α-synuclein oligomer within endoplasmic reticulum occurs in α-synucleinopathy in vivo. J Neurosci. 2012;32(10):3301–3305.
   PubMed Web of Science ®Google Scholar
• Colla E, Coune P, Liu Y, et al. Endoplasmic reticulum stress is important for the manifestations of α-synucleinopathy in vivo. J Neurosci. 2012;32(10):3306–3320.
   PubMed Web of Science ®Google Scholar
• Lee DY, Lee KS, Lee HJ, et al. Activation of PERK signaling attenuates Abeta-mediated ER stress. PLoS One. 2010;5(5):e10489.
   Web of Science ®Google Scholar
• Reijonen S, Putkonen N, Nørremølle A, Lindholm D, Korhonen L. Inhibition of endoplasmic reticulum stress counteracts neuronal cell death and protein aggregation caused by N-terminal mutant huntingtin proteins. Exp Cell Res. 2008;314(5):950–960.
   Web of Science ®Google Scholar
• Nakka VP, Gusain A, Raghubir R. Endoplasmic reticulum stress plays critical role in brain damage after cerebral ischemia/reperfusion in rats. Neurotox Res. 2010;17(2):189–202.
   PubMed Web of Science ®Google Scholar
• Halliday M, Mallucci GR. Targeting the unfolded protein response in neurodegeneration: A new approach to therapy. Neuropharmacology. 2014;76(Pt A):169–174.
   PubMedGoogle Scholar
• Chiesa R, Piccardo P, Quaglio E, et al. Molecular distinction between pathogenic and infectious properties of the prion protein. J Virol. 2003;77(13):7611–7622.
   PubMed Web of Science ®Google Scholar
• Sandberg MK, Al-Doujaily H, Sharps B, Clarke AR, Collinge J. Prion propagation and toxicity in vivo occur in two distinct mechanistic phases. Nature. 2011;470(7335):540–542.
   PubMed Web of Science ®Google Scholar
• Silveira JR, Raymond GJ, Hughson AG, et al. The most infectious prion protein particles. Nature. 2005;437(7056):257–261.
   PubMed Web of Science ®Google Scholar
• Simoneau S, Rezaei H, Salès N, et al. In vitro and in vivo neurotoxicity of prion protein oligomers. PLoS Pathog. 2007;3(8):e125.
   PubMed Web of Science ®Google Scholar